Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Mehr anzeigen
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Jan. 2, 2025 CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®...
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024 CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®...
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Dec. 3, 2024 Outcomes study...
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 25, 2024 CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease PR Newswire CAMBRIDGE, Mass., Nov. 14, 2024 Akebia continues to publish important results of FO2CUS...
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 12, 2024 CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics®...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.14 | -7.32984293194 | 1.91 | 1.94 | 1.75 | 1810597 | 1.86384848 | CS |
| 4 | -0.03 | -1.66666666667 | 1.8 | 1.975 | 1.74 | 1956437 | 1.85440779 | CS |
| 12 | 0.45 | 34.0909090909 | 1.32 | 2.17 | 1.3 | 2216383 | 1.85146884 | CS |
| 26 | 0.785 | 79.6954314721 | 0.985 | 2.17 | 0.9849 | 1954459 | 1.60542414 | CS |
| 52 | 0.17 | 10.625 | 1.6 | 2.48 | 0.8 | 2929685 | 1.52680155 | CS |
| 156 | -0.42 | -19.1780821918 | 2.19 | 2.93 | 0.241 | 3615058 | 1.00183931 | CS |
| 260 | -5.25 | -74.7863247863 | 7.02 | 13.78 | 0.241 | 3675161 | 2.2304849 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
